Regulatory shifts, market-access playbooks and funding intelligence — written to be read here and shared straight to LinkedIn.
Non-dilutive money isn't just cheaper capital. Used in the right order, it postpones valuation and changes what your next equity round is worth. The sequencing is the strategy.
Read article →A refreshed GL-04, a second edition of the AI healthcare guidelines, and a reliance route that can turn an existing approval into a shortcut. Singapore is easier to enter than it looks in 2026 — if you read the new rules correctly.
Read article →One FDA AI guidance is final and enforceable. The one everyone quotes is still a draft. Knowing which is which is the difference between a clean submission and a refuse-to-accept letter.
Read article →The European and Singaporean funding programmes that extend runway before you give away equity.
Read article →A practical framework for structuring evidence once and reusing it across MDR, FDA and HSA submissions.
Read article →How the AI Act layers onto MDR for AI-based medical devices — and the documentation to start building today.
Read article →